|
MX2017000053A
|
|
Methods for the treatment of hepatitis b and hepatitis d virus infections.
|
|
TW201408309A
|
|
Methods for the treatment of hepatitis b and hepatitis d infections
|
|
TW201408308A
|
|
Oligonucleotide chelate complex-polypeptide compositions and methods
|
|
AR091065A1
|
|
A PHARMACEUTICAL FORMULATION THAT INCLUDES AN ANTIVIRAL OLIGONUCLEOTIDE CHELATE FOR THE TREATMENT OF AN ANTI-VIRAL INFECTION
|
|
KR20150082685A
|
|
Oligonucleotide chelate complexes
|
|
CA2746981A1
|
|
Methods for inhibition of apolipoprotein h
|
|
WO2007022642A2
|
|
Anti-inflammatory molecules and their uses
|
|
CA2624686A1
|
|
Therapeutic molecules and their uses
|
|
WO2006122409A1
|
|
Antimicrobial molecules and their uses
|
|
WO2006119643A1
|
|
Anti-ocular angiogenesis molecules and their uses
|
|
WO2006119619A1
|
|
Oligonucleotides inhibiting cell proliferation
|
|
WO2006130949A1
|
|
Anti amyloid-related disease molecules and their uses
|
|
WO2006096995A1
|
|
Sulfur oligonucleotides having antiviral activities
|
|
CA2584207A1
|
|
Antiviral oligonucleotides
|
|
MX2007004506A
|
|
Antiviral oligonucleotides.
|
|
CN101084232A
|
|
Antiviral oligonucleotides
|
|
WO2005082921A1
|
|
Method for inhibiting cellular proliferation
|
|
US2005196382A1
|
|
Antiviral oligonucleotides targeting viral families
|
|
AU2004271807A1
|
|
Oligonucleotides targeting prion diseases
|
|
US2007123480A1
|
|
Oligonucleotides targeting prion diseases
|
